BRPI0920927A2 - derivados de azaquinolinona e usos dos mesmos - Google Patents

derivados de azaquinolinona e usos dos mesmos

Info

Publication number
BRPI0920927A2
BRPI0920927A2 BRPI0920927A BRPI0920927A BRPI0920927A2 BR PI0920927 A2 BRPI0920927 A2 BR PI0920927A2 BR PI0920927 A BRPI0920927 A BR PI0920927A BR PI0920927 A BRPI0920927 A BR PI0920927A BR PI0920927 A2 BRPI0920927 A2 BR PI0920927A2
Authority
BR
Brazil
Prior art keywords
azaquinolinone
derivatives
azaquinolinone derivatives
Prior art date
Application number
BRPI0920927A
Other languages
English (en)
Inventor
E Duggan Mark
Original Assignee
Link Medicine Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Link Medicine Corp filed Critical Link Medicine Corp
Publication of BRPI0920927A2 publication Critical patent/BRPI0920927A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
BRPI0920927A 2008-11-13 2009-11-13 derivados de azaquinolinona e usos dos mesmos BRPI0920927A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11430308P 2008-11-13 2008-11-13
US23143409P 2009-08-05 2009-08-05
PCT/US2009/064404 WO2010057006A1 (en) 2008-11-13 2009-11-13 Azaquinolinone derivatives and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0920927A2 true BRPI0920927A2 (pt) 2019-09-24

Family

ID=41460195

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920927A BRPI0920927A2 (pt) 2008-11-13 2009-11-13 derivados de azaquinolinona e usos dos mesmos

Country Status (12)

Country Link
US (2) US8343996B2 (pt)
EP (1) EP2370436A1 (pt)
JP (1) JP2012508768A (pt)
CN (1) CN102369202A (pt)
AU (1) AU2009313927A1 (pt)
BR (1) BRPI0920927A2 (pt)
CA (1) CA2743717A1 (pt)
IL (1) IL212836A0 (pt)
MX (1) MX2011005096A (pt)
NZ (1) NZ593090A (pt)
WO (1) WO2010057006A1 (pt)
ZA (1) ZA201103635B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
EP2155197A4 (en) * 2007-03-09 2011-10-12 Link Medicine Corp TREATMENT OF LYSOSOMAL STORAGE DISEASES
PE20110711A1 (es) 2008-11-19 2011-10-11 Envivo Pharmaceuticals Inc Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmaceuticamente aceptables de la misma
RU2011150248A (ru) * 2009-05-11 2013-06-20 Энвиво Фармасьютикалз, Инк. Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы
US8598203B2 (en) 2009-07-30 2013-12-03 Teva Pharmaceutical Industries, Ltd. Treatment of Crohn's disease with laquinimod
PL3064206T3 (pl) * 2009-08-10 2020-02-28 Active Biotech Ab Leczenie choroby Huntingtona z zastosowaniem lakwinimodu
CA2791709A1 (en) 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
BR112012021905A2 (pt) 2010-03-03 2015-09-29 Teva Pharma tratamento de nefrite lúpica usando laquinimod
CA2989633A1 (en) 2010-05-17 2011-11-24 Forum Pharmaceuticals Inc. A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
WO2012094612A1 (en) * 2011-01-07 2012-07-12 Zenyaku Kogyo Kabushikikaisha Method of treating essential tremor
MX2014004420A (es) 2011-10-12 2014-07-09 Teva Pharma Tratamiento de esclerosis multiple con combinacion de laquinimod y fingolimod.
BR112014024672A8 (pt) 2012-04-04 2018-04-03 Ivax Int Gmbh Composições farmacêuticas para terapia de combinação
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
TW201410243A (zh) * 2012-08-13 2014-03-16 Teva Pharma 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
AU2013323131A1 (en) * 2012-09-27 2015-05-07 Teva Pharmaceutical Industries Ltd. Laquinimod and pridopidine for treating neurodegenerative disorders
GB201514489D0 (en) 2015-08-14 2015-09-30 Bergen Teknologioverføring As Hyperphenylalaninemia
US11045441B2 (en) * 2015-10-13 2021-06-29 Wisconsin Alumni Research Foundation Use of retinoic acid and analogs thereof to treat central neural apneas
EP3628009A4 (en) * 2017-05-19 2021-03-24 The Regents of The University of Colorado, A Body Corporate COMPOSITIONS AND PROCESSES FOR IMPROVING PERCEPTION
JP7210483B2 (ja) * 2017-06-30 2023-01-23 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新規アザキノリン誘導体
WO2019093389A1 (ja) 2017-11-08 2019-05-16 公益財団法人 東京都医学総合研究所 知的障害又は自閉症治療薬
WO2021013232A1 (en) * 2019-07-25 2021-01-28 The Hong Kong University Of Science And Technology Aie-active photosensitizer for selective bacterial elimination and cancer cell ablation
KR102212722B1 (ko) * 2019-12-23 2021-02-08 환인제약 주식회사 로피니롤을 포함하는 마이크로스피어 및 이를 함유하는 주사제 조성물
CN112656791A (zh) * 2021-02-01 2021-04-16 洪楠方 一种治疗枫糖尿病的化合物
US20240201205A1 (en) * 2022-09-15 2024-06-20 The Regents Of The University Of California Method for detecting neurological diseases using supramolecule polymer therapeutics
CN116687914B (zh) * 2023-08-07 2024-01-16 山东师范大学 一种治疗非酒精性脂肪肝的药物

Family Cites Families (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU169186B (pt) 1974-06-13 1976-10-28
US4110536A (en) 1977-04-18 1978-08-29 Miles Laboratories, Inc. Derivatives of 5-(indol-3-yl)hydantoin
US4576957A (en) 1984-07-05 1986-03-18 American Cyanamid Company N-(Substituted phenyl)-N'-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)alkyl]ureas
US5017584A (en) 1984-12-20 1991-05-21 Sterling Drug Inc. Antidepressant 2-(4,5-dihydro-1H-imidazolyl)-dihydro-1H-indoles, -1,2,3,4-tetrahydroquinolines and -1H-indoles, and methods of use thereas
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
IT1222563B (it) 1986-09-30 1990-09-05 Brasil Compressores Sa Compressore ermetico ad albero a gomiti orizzontale
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US4939174A (en) 1988-02-26 1990-07-03 Shashoua Victor E Appetite suppression with dopamine-fatty acid conjugates
US4933324A (en) 1988-02-26 1990-06-12 Shashoua Victor E Fatty acid-neuroactive drug conjugate as a prodrug
US6107499A (en) 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US4863962A (en) 1988-03-02 1989-09-05 Fidia-Georgetown Institute For The Neurosciences D-DOPA, pharmaceutically acceptable salts thereof, and methods of treating Parkinson's disease
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6632626B1 (en) 1990-04-18 2003-10-14 Board Of Regents, The University Of Texas System Methods of assaying farnesyl transferase
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5185248A (en) 1990-05-08 1993-02-09 E. R. Squibb & Sons, Inc. Farnesyl-protein transferase assay for identifying compounds that block neoplastic transformation
US5374615A (en) 1990-10-31 1994-12-20 E. R. Squibb & Sons, Inc. Indole- and benzimidazole-substituted imidazole and benzimidazole derivatives
US5633376A (en) 1990-12-28 1997-05-27 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5371227A (en) 1991-10-28 1994-12-06 Synthelabo Quinoline derivatives, process for their preparation, and their therapeutic applications
US5322950A (en) 1991-12-05 1994-06-21 Warner-Lambert Company Imidazole with angiotensin II antagonist properties
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
GB2267966A (en) 1992-06-17 1993-12-22 Merck & Co Inc A fluorescence assay for farnesyl protein transferase activity
US5726197A (en) 1992-11-02 1998-03-10 Syntex (U.S.A.) Inc. Isoindolinyl derivatives
EP0670320A4 (en) * 1992-12-01 1997-05-02 Green Cross Corp DERIVATIVE OF 1,8-NAPHTHYRIDIN-2-ONE AND USE OF THIS DERIVATIVE.
US5523317A (en) 1993-07-05 1996-06-04 Nippon Chemiphar Co., Ltd. Method of reducing blood pressure
US5719148A (en) 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US6365588B1 (en) 1993-10-15 2002-04-02 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
CZ285481B6 (cs) 1993-12-17 1999-08-11 The Procter & Gamble Company 6-(2-imidazolinylamino)chinolinové sloučeniny použitelné jako alfa-2-adrenoceptorové agonisté
US5576437A (en) 1993-12-17 1996-11-19 The Procter & Gamble Company 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5856326A (en) 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9515975D0 (en) 1995-08-04 1995-10-04 Zeneca Ltd Chemical compounds
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
EA000710B1 (ru) * 1995-12-08 2000-02-28 Жансен Фармасетика Н.В. (имидазол-5-ил)метил-2-хинолиноновые производные, ингибирующие фарнезилпротеин-трансферазу
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US5859012A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5919785A (en) 1996-04-03 1999-07-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
TW436484B (en) 1996-04-24 2001-05-28 Dev Center Biotechnology 1,2,3,4-tetrahydroisoquinoline derivatives having a nitrogen-containing heterocyclic methyl substituent, the preparation process and pharmaceutical composition thereof
EP0918771A4 (en) 1996-07-15 2001-02-07 Bristol Myers Squibb Co THIADIOXOBENZODIAZEPINES FOR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS
US5925757A (en) 1996-07-26 1999-07-20 Schering Corporation Method for preparing carboxamides
JPH10215175A (ja) 1996-11-29 1998-08-11 Sony Corp Ｐｌｌ回路及び信号再生装置
US5939439A (en) 1996-12-30 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6013662A (en) 1996-12-30 2000-01-11 Rhone-Poulenc Rorer S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
CZ296959B6 (cs) 1997-04-25 2006-08-16 Janssen Pharmaceutica N. V. Chinazolon, zpusob a meziprodukt pro jeho výrobu a farmaceutický prostredek s jeho obsahem
US6060038A (en) 1997-05-15 2000-05-09 Merck & Co., Inc. Radiolabeled farnesyl-protein transferase inhibitors
DK0988038T3 (da) 1997-06-02 2002-12-02 Janssen Pharmaceutica Nv Anvendelse af (imidazol-5-yl)methyl-2-quinolinon derivater til hæmning af glat muskelcelleproliferation
US5939416A (en) 1997-06-17 1999-08-17 Schering Corporation Benzo (5,6) cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors
US6576639B1 (en) 1997-06-17 2003-06-10 Schering Corporation Compounds for the inhibition of farnesyl protein transferase
US6358968B1 (en) 1997-06-17 2002-03-19 Schering Corporation N-substituted urea inhibitors of farnesyl-protein transferase
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
EE200000077A (et) 1997-08-15 2000-12-15 Duke University Östrogeenist sõltuvate haiguste ja häirete vältimise ja ravi meetod
US6103487A (en) 1997-08-27 2000-08-15 Merck & Co., Inc. Method of treating cancer
US6387903B1 (en) 1997-08-27 2002-05-14 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6458783B1 (en) 1997-09-29 2002-10-01 Bristol-Myers Squibb Company Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
WO1999038914A2 (en) 1998-02-03 1999-08-05 Continental Pet Technologies, Inc. Enhanced oxygen-scavenging polymers, and packaging made therefrom
US6160118A (en) 1998-07-01 2000-12-12 Merck & Co., Inc. Process for the synthesis of substituted piperazinones via Mitsunobu reaction
AU754554B2 (en) 1998-07-02 2002-11-21 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CN1152716C (zh) 1998-07-06 2004-06-09 詹森药业有限公司 具体内射线感受性的法呢基蛋白质转移酶抑制剂
KR100674122B1 (ko) 1998-07-06 2007-01-26 얀센 파마슈티카 엔.브이. 관절증 치료용 파네실 단백질 트랜스퍼라제 억제제
US6156746A (en) 1998-08-25 2000-12-05 Bristol-Myers Squibb Company 1,2,5-benzothiadiazepine-1,1-dioxides with n-2 imidazolylalkyl substituents
EA200100135A1 (ru) 1998-08-27 2001-08-27 Пфайзер Продактс Инк. Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов
US20020064142A1 (en) 1998-10-13 2002-05-30 Franklin P. Antonio Base station architecture
US6329376B1 (en) 1998-10-29 2001-12-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2477400A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
DK1140935T3 (da) 1998-12-23 2003-09-01 Janssen Pharmaceutica Nv 1,2-anellerede quinolinderivater
TR200201296T2 (tr) 1999-02-11 2002-07-22 Pfizer Products Inc. Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri
WO2000059930A1 (en) 1999-04-05 2000-10-12 Merck & Co., Inc. A method of treating cancer
US6373717B1 (en) 1999-07-02 2002-04-16 International Business Machines Corporation Electronic package with high density interconnect layer
EP1202747A1 (en) 1999-07-20 2002-05-08 Merck & Co., Inc. Sustained release drug dispersion delivery device
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
US6420122B1 (en) 1999-09-27 2002-07-16 Massachusetts Institute Of Technology Methods of screening for agents that inhibit aggregation of polypeptides
GB9930318D0 (en) 1999-12-22 2000-02-09 Zeneca Ltd Novel compounds
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
DE60118889T2 (de) 2000-02-04 2006-11-30 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
US20020052380A1 (en) 2000-02-18 2002-05-02 Dinsmore Christopher J. Inhibitors of prenyl-protein transferase
US20020010184A1 (en) 2000-02-18 2002-01-24 Dinsmore Christopher J. Inhibitors of prenyl-protein transferase
WO2001062234A2 (en) 2000-02-24 2001-08-30 Janssen Pharmaceutica N.V. Dosing regimen
CA2397349A1 (en) 2000-02-29 2001-09-07 Ivan David Horak Farnesyl protein transferase inhibitor combinations with an her2 antibody
US20030186925A1 (en) 2000-02-29 2003-10-02 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
JP2003525239A (ja) 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
EP1261356A2 (en) 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
CA2397694A1 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica Inc. Farnesyl protein transferase inhibitor combinations
US20030078281A1 (en) 2000-02-29 2003-04-24 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
AU2001240658A1 (en) 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with camptothecin compounds
JP2003525255A (ja) 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルタンパク質トランスフェラーゼ阻害剤とさらなる抗癌剤との組み合わせ剤
AU2001249091A1 (en) 2000-03-03 2001-09-17 Eisai Co. Ltd. Novel methods using cholinesterase inhibitors
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US20010051642A1 (en) 2000-04-17 2001-12-13 Kyunghye Ahn Method for treating Alzheimer's disease
US6844357B2 (en) 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
AU1550201A (en) 2000-06-08 2001-12-17 Kaneka Corporation Process for the production of sulfonic esters
MXPA02012724A (es) 2000-06-23 2003-05-14 Du Pont Anillo de distribucion de vapor para maquinas de hilar.
AU2001293829A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-((substituted phenyl)methyl)-quinoline and quinazoline derivatives
ES2313991T3 (es) 2000-09-25 2009-03-16 Janssen Pharmaceutica Nv Derivados de 6-heterociclilmetil-quinolina y quinazolina que inhiben la farnesil transferasa.
AU2001293835A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
AU2001293826A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
GB0023915D0 (en) 2000-09-29 2000-11-15 Inst Of Ophthalmology Treatment of neuroinflammatory disease
AU2002211427A1 (en) 2000-10-05 2002-04-15 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
WO2002042296A1 (en) 2000-11-21 2002-05-30 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
US20040044032A1 (en) 2000-11-28 2004-03-04 End David William Farnesyl protein transfer inhibitors for the treatment of inflammatory bowel disease
EP1395577A1 (en) 2000-12-19 2004-03-10 Pfizer Products Inc. Crystal forms of 6- (4-chloro-phenyl)-hydroxy-(-3-methyl-3h-imidaol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
EP1347966B1 (en) 2000-12-27 2006-03-08 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
US6645966B2 (en) 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
EP1383490B1 (en) 2001-03-14 2012-04-25 Bristol-Myers Squibb Company Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases
US20020151563A1 (en) 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6949642B2 (en) 2001-04-19 2005-09-27 Bristol-Myers Squibb Co. Production of tertiary amines by reductive amination
US20040157773A1 (en) 2001-04-25 2004-08-12 End David William Farnesyl protein transferase inhibitors for treating cachexia
US7323635B2 (en) 2001-06-15 2008-01-29 University Of Massachusetts Photovoltaic cell
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
US20030134846A1 (en) 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
EP1443936A4 (en) 2001-11-13 2006-01-11 Bristol Myers Squibb Co PROCESS FOR THE PREPARATION OF 3,7-DISUBSTITUE-2,3,4,5-TETRAHYDRO-1H-1,4-BENZODIAZEPINE COMPOUNDS
MXPA04005425A (es) 2001-12-03 2004-10-11 Schering Corp Uso de inhibidores de farnesil proteina transferasa y por lo menos dos agentes antineoplasicos en el tratamiento de cancer.
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
DE60314381T2 (de) 2002-03-22 2008-02-21 Janssen Pharmaceutica N.V. Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
US20030050323A1 (en) 2002-08-28 2003-03-13 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
US20030060480A1 (en) 2002-08-28 2003-03-27 Horak Ivan David Farnesyl protein transferase inhibitor combinations with vinca alkaloids
US20030125268A1 (en) 2002-08-28 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
AU2003272539A1 (en) 2002-09-17 2004-04-08 New York University Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors
DE60325744D1 (de) 2002-09-27 2009-02-26 Sod Conseils Rech Applic Zubereitung zur behandlung des nasopharyngalen carcinom und verwendung derselben
US7838531B2 (en) 2002-10-18 2010-11-23 The United States Of America As Represented By The Department Of Health And Human Services Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
EP1594459B1 (en) 2002-12-30 2010-02-17 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7053223B2 (en) 2003-02-14 2006-05-30 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US20070054886A1 (en) 2003-05-23 2007-03-08 Ramot At Tel Aviv University, Ltd. Ras antagonists for treating neurodegenerative disorders
US20050154451A1 (en) 2003-12-18 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
WO2005089518A2 (en) 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
US20070293539A1 (en) 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US20050272722A1 (en) 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050288298A1 (en) 2004-03-18 2005-12-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
CA2559285A1 (en) 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20060106060A1 (en) 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
WO2005105783A1 (en) 2004-05-03 2005-11-10 Janssen Pharmaceutica N.V. Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline
WO2005117864A1 (en) 2004-05-28 2005-12-15 Astrazeneca Ab Combination product comprising anastrozole and a dual prenyl transferase inhibitor
MX2007001727A (es) 2004-08-13 2007-04-20 Genentech Inc Compuestos a base de 2-amido-tiazol que exhiben actividad inhibidora de enzima que utiliza atp y composiciones y usos de los mismos.
PT2362218E (pt) 2004-11-05 2014-12-04 Janssen Pharmaceutica Nv Uso terapêutico de inibidores de farnesiltransferase e métodos para monitorizar a eficácia do mesmo
EP1656931A1 (en) 2004-11-15 2006-05-17 Exonhit Therapeutics SA Compounds which inhibits protein prenylation ( e.g. geranylgeranyltransferase or farnesyltransferase inhibitors) for treating Parkinson's disease
US20060194821A1 (en) 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US6988461B1 (en) * 2005-04-15 2006-01-24 James Joseph B Telescoping boat tower apparatus
WO2006116716A2 (en) 2005-04-27 2006-11-02 University Of Florida Materials and methods for enhanced degradation of mutant proteins associated with human disease
JP2009511450A (ja) 2005-10-07 2009-03-19 ノバルティス アクチエンゲゼルシャフト ニロチニブとファルネシルトランスフェラーゼ阻害剤の組合せ
ATE475408T1 (de) 2005-10-14 2010-08-15 Janssen Pharmaceutica Nv Formulierungen von tipifarnib zur intravenösen verabreichung
EP1968591A4 (en) 2005-12-23 2010-02-17 Link Medicine Corp TREATMENT OF SYNUCLEINOPATHIES
GB0605689D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic compounds
US20070287706A1 (en) 2006-05-18 2007-12-13 Dickson John K Jr Certain substituted quinolones, compositions, and uses thereof
CA2655787A1 (en) 2006-06-28 2008-01-03 Merck And Co., Inc. Benzyl-substituted quinolone m1 receptor positive allosteric modulators
DK2046740T3 (da) 2006-07-22 2012-08-20 Oxagen Ltd Forbindelser med CRTH2-antagonistisk virkning
EP2155197A4 (en) 2007-03-09 2011-10-12 Link Medicine Corp TREATMENT OF LYSOSOMAL STORAGE DISEASES
WO2008137692A1 (en) 2007-05-03 2008-11-13 Link Medicine Corporation Treatment of synucleinopathies
WO2009036275A1 (en) 2007-09-13 2009-03-19 Link Medicine Corporation Treatment of neurodegenerative diseases using indatraline analogs
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
DK2276485T3 (da) 2008-04-24 2014-10-13 Bristol Myers Squibb Co Anvendelse af epothilon d i behandling af tau-associerede sygdomme,herunder alzheimers sygdom

Also Published As

Publication number Publication date
WO2010057006A9 (en) 2010-09-16
US20130165473A1 (en) 2013-06-27
US20100130540A1 (en) 2010-05-27
NZ593090A (en) 2013-06-28
CA2743717A1 (en) 2010-05-20
WO2010057006A1 (en) 2010-05-20
EP2370436A1 (en) 2011-10-05
US8343996B2 (en) 2013-01-01
ZA201103635B (en) 2012-10-31
JP2012508768A (ja) 2012-04-12
AU2009313927A1 (en) 2010-05-20
MX2011005096A (es) 2011-11-18
IL212836A0 (en) 2011-07-31
CN102369202A (zh) 2012-03-07

Similar Documents

Publication Publication Date Title
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
BRPI0908906A2 (pt) compostos heterocíclicos e usos dos mesmos
BRPI0914682A2 (pt) compostos de heteroarila e usos dos mesmos
BR112012003709A2 (pt) compostos heterocíclicos e usos dos mesmos
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
BRPI1014997A2 (pt) compostos heteroarila e usos dos mesmos
BRPI1011404A2 (pt) mutantes e usos dos mesmos
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
BRPI0922807A2 (pt) imonuglobulinas de domínio variável duplo e usos dos mesmos
BRPI1010024A2 (pt) derivados de aminopirrolidinona e uso dos mesmos
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
BRPI0922691A2 (pt) conjugados de leptina e análogo de leptina e usos dos mesmos
BRPI0909469A2 (pt) compostos de oximetileno de arila e usos dos mesmos
BRPI1013943A2 (pt) Composto cetais e usos dos mesmos.
BRPI0912480A2 (pt) compostos de monoalquiltina de alta pureza e usos dos mesmos
BR112012001260A2 (pt) conjugados de epsilon-polilisina e o emprego dos mesmos
BR112013015592A8 (pt) derivados de biciclo-[3.2.1]-octilamida e usos dos mesmos
BRPI0821310A2 (pt) Conjugados polipeptídeos-ácido nucleico e usos dos mesmos
BRPI0914891A2 (pt) agonistas de aril gpr119 e usos dos mesmos
BR112012006501A2 (pt) polipeptídios e usos dos mesmos
BRPI0922790A2 (pt) peptídeos de ligação sparc e usos dos mesmos
BRPI0922689A2 (pt) conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos
BRPI0910702A2 (pt) polipeptídeos de fator ix modificados e usos dos mesmos
BRPI0920209A2 (pt) conjugados de agonistas de glp-1 e usos dos mesmos
BRPI0923283A2 (pt) conjugados terapêuticos de peptídeo e usos dos mesmos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.